20 Jan 2020
Lewis Cameron

Lewis is an experienced senior executive with a proven track record in the global pharmaceutical services sector, including oncology expertise, and significant M&A experience. He was the Head of Global Clinical Development at Covance, the CRO division of Laboratory Corporation Holdings of America (LabCorp), from 2017 to 2019, where as an integral part of the senior management team, they achieved $4.3 billion of revenues in 2018. Prior to that, he was the Executive Vice President of Oncology and the General Manager for CEE and APAC Regions at Chiltern International from 2014 to 2017, where he was instrumental in driving the integration of a number of acquired businesses, had oversight of the client portfolio in multiple therapeutic areas, and led the growth and development of the clinical business.

Lewis also brings experience from the client side of the pharmaceutical services sector, having been Chief Executive Officer (CEO) of a biotech business, Avillion LLP, from 2012 to 2014 where, following the venture capital seed financing of the company, he signed a significant in-licensing deal with Pfizer for the further development of the company’s innovative cancer therapies. Prior to that, Lewis was CEO of Clearstone Central Laboratories, a global central lab organisation based in Paris, France, from January 2010 to July 2011, where he achieved an operational and financial turnaround resulting in its successful acquisition by LabCorp.